LPCN Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
2.1M
0
0
-100.0%
1.1M
0
Cost of Revenue
0
0
0
0
0
Gross Profit
2.1M
0
0
-100.0%
1.1M
0
Operating Expenses
3.2M
+4.2%
3.0M
-23.6%
4.0M
+8.4%
3.7M
+5.3%
3.5M
R&D
2.1M
+1.4%
2.0M
-26.2%
2.8M
+3.2%
2.7M
-1.1%
2.7M
SG&A
1.1M
+9.8%
991.0K
-17.7%
1.2M
+22.5%
983.4K
+28.1%
767.8K
Operating Income
-1058597
+65.1%
-3032345
+23.6%
-3968861
-57.8%
-2515801
+27.6%
-3475614
EBITDA
-1043950
+65.4%
-3017697
+23.7%
-3954047
-58.1%
-2500820
+27.8%
-3461491
Net Income
-666192
+74.6%
-2622595
+28.6%
-3671894
-54.9%
-2370084
+25.6%
-3186832
EPS (Basic)
$-0.08
+75.0%
$-0.32
+40.7%
$-0.54
-28.6%
$-0.42
+28.8%
$-0.59
EPS (Diluted)
$-0.08
+75.0%
$-0.32
+40.7%
$-0.54
-54.3%
$-0.35
+40.7%
$-0.59
Shares (Diluted)
8.2M
+0.3%
8.2M
+20.9%
6.8M
+1.1%
6.7M
+24.1%
5.4M
Lipocine (LPCN) — Financials